Vetofol

Quick links to important sections

Vetofol

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vetofol

Vetofol: Defining its Identity and Composition

Property Description
Active Ingredient Doxycycline Hyclate (INN)
Form Oral Capsule, Tablet, or Suspension
Pharmacological Class Tetracycline-class Antimicrobial / Immunomodulator
Common Use Management of bacterial and chronic inflammatory conditions
Origin Semi-synthetic

Vetofol is a prescription medication primarily known in veterinary medicine as a Tetracycline-class Antimicrobial, containing the active ingredient Doxycycline Hyclate. It is formulated into easy-to-administer oral capsules, flavored tablets, or suspensions designed for accurate dosing.

While Doxycycline is primarily recognized for its antibiotic capabilities against a broad spectrum of bacteria, Vetofol is clinically recognized for its versatility. Its formulation is often prescribed for two distinct purposes: high-dose treatment of common bacterial infections and low-dose treatment for chronic inflammation. Specifically, the non-antimicrobial properties of Doxycycline work to inhibit tissue-damaging enzymes. The drug works by selectively calming the immune response, which helps slow down tissue breakdown. The active substance is semi-synthetic in origin, ensuring a consistent and reliable product profile.


What is Vetofol Used For?

Vetofol's general therapeutic purpose is to provide essential treatment for systemic bacterial infections and offer long-term support for symptoms associated with chronic inflammatory diseases. It is utilized as a supportive treatment to control the inflammatory cycle.

The medication's differentiating factor lies in this dual application. In one typical scenario, it is used to treat infections such as tick-borne diseases; in another, it is prescribed for the management of chronic tissue degradation, particularly as an adjunct therapy for periodontal (gum) disease. Low-dose Doxycycline reduces systemic inflammation without the risk of developing bacterial resistance typically associated with prolonged use. This means that the medicine can help relieve chronic irritation and support healing without disturbing the patient's natural microbial balance.

Regulatory References

  1. NIH Non-antimicrobial Doxycycline

What side effects are possible with Vetofol?

Possible Side Effects and Safety Information

The official regulatory safety profile for Vetofol (Doxycycline Hyclate) is structured around frequency-classified adverse reactions, specific organ systems affected, and constraints for vulnerable populations.

Adverse Reaction Classifications

Common adverse reactions documented in official sources include gastrointestinal effects such as nausea, vomiting, diarrhea, and anorexia. Dermatological effects are also common, notably photosensitivity, which presents as an exaggerated sunburn reaction. Uncommon effects may include exfoliative dermatitis.

Reactions are grouped by System-Organ-Classes; key areas include the Gastrointestinal System, Skin, and Nervous System (headache, dizziness). Rare but serious systemic reactions include hepatotoxicity (liver damage) and certain blood disorders.

Serious Safety Considerations

The label specifies the potential for serious adverse reactions, including Intracranial Hypertension (pseudotumor cerebri) and severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome (SJS). Furthermore, use is associated with the risk of Clostridium difficile-Associated Diarrhea (CDAD), which can occur even after treatment is stopped.

Population-Specific Restrictions

Official documents impose strict limitations on use during periods of development. The medication is generally not recommended for use in children under 8 years or during the last half of pregnancy due to the risk of permanent tooth discoloration (yellow-gray-brown) and potential effects on bone growth. For long-term therapy, periodic laboratory evaluations of hematopoietic, renal, and hepatic function are recommended.

Overdose and Emergency Response

Over-exposure to Vetofol is documented to result in an increased incidence of common side effects, including heightened gastrointestinal distress, such as nausea, vomiting, and rash. The physiological risks of overdose involve excessive systemic accumulation of the drug, which can lead to documented toxicities affecting the liver and the Central Nervous System.

A serious manifestation associated with over-exposure is Intracranial Hypertension (pseudotumor cerebri). Any visual disturbance during treatment warrants a prompt ophthalmologic evaluation because of the potential for permanent visual loss linked to this condition. The risk of accumulation is particularly elevated in patients with impaired renal function, where serum level determinations may be advised by regulatory documents. In infants, bulging fontanels are a documented clinical sign of elevated pressure.

Management is defined as symptomatic and supportive treatment. Regulatory guidance explicitly mandates that immediate medical attention be sought for life-threatening symptoms, including trouble breathing, seizure, collapse, or signs of severe allergic reaction (such as swelling of the face or throat). In such cases, contact with emergency services is required.

Therapeutic Uses of Vetofol

What Vetofol Treats: Main Uses and Benefits

Vetofol is relevant for symptomatic management across two distinct clinical areas: addressing acute symptomatic episodes and offering supportive therapeutic benefit for inflammatory conditions. This medication is relevant across therapeutic areas that involve systemic or localized discomfort. The medication is considered relevant for its established uses.


Managing Acute Systemic and Tick-Borne Infections

Vetofol is commonly used to help manage systemic bacterial infections, including specific tick-borne diseases. It is applied across domains where additional symptomatic support is needed when patients experience acute signs of illness such as fever and lethargy. This medication may assist with managing the bacterial component of the infection, providing support that helps ease the overall symptom burden of the acute episode.


Supportive Management for Chronic Inflammation and Tissue Health

This medication is relevant for conditions involving inflammatory or irritative processes where the body’s own response can lead to tissue strain, such as conditions involving localized irritative states. Vetofol is relevant for its supportive action, used when groups of symptoms related to chronic tissue degradation appear suddenly or fluctuate. This offers a key long-term benefit by assisting in controlling chronic irritation and supports general well-being during symptomatic phases. Vetofol is utilized as an adjunct therapeutic support in the management of periodontal (gum) disease, addressing the localized discomfort and tissue strain in the oral cavity. This provides support that assists with managing symptoms related to tissue strain, contributing to improved comfort during periods of heightened symptoms associated with dental care.


Quick Fact: Relief for Inflammatory Symptoms

Vetofol may assist with maintaining functional stability by managing the symptomatic impact of persistent inflammation and tissue degradation.

Regulatory References

  1. NIH MedlinePlus overview of Doxycycline

Eligibility and Restrictions for Use

Vetofol's eligibility is strictly defined by regulatory authorities based on its classification as a tetracycline-class drug. Absolute contraindications prohibit its use in several key populations. The medicine is contraindicated for anyone with a known hypersensitivity to doxycycline or any other tetracycline-class antibiotic. It is also contraindicated for pregnant women and children under 8 years of age due to the confirmed risk of permanent dental discoloration and effects on bone development.

Use is not recommended for nursing or breastfeeding mothers. The official label requires restricted use for children aged 8 to 12 years; use in this age group is only permitted if other treatments are unavailable or unsuitable. Eligibility is also conditioned by organ status: the medicine is contraindicated in patients with severe hepatic function disorders and advised with caution in those with non-severe impaired liver function. The medicine is generally approved for use in adults and older adults under standard conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify interactions with Vetofol ( Doxycycline Hyclate) across several pharmacological domains. The following table summarizes the key interaction statements based on government labeling:

Interaction Classification Interacting Substance Official Regulatory Statement
Formal Restrictions Isotretinoin (Retinoids) Avoid concomitant use due to officially documented risk of Intracranial Hypertension.
Methoxyflurane Co-administration may result in fatal renal toxicity.
Penicillin (Antibiotics) Regulatory documents advise to avoid co- administration.
Reduced Exposure (PK) Antacids (Al, Ca, Mg), Iron Preparations, Bismuth Subsalicylate Absorption is officially impaired by co-administration.
Accelerated Clearance (PK) Phenytoin, Carbamazepine, Barbiturates These substances officially decrease the half- life of Doxycycline.
Pharmacodynamic Effects Anticoagulants May require downward adjustment of the anticoagulant dosage.
Oral Contraceptives Concurrent use may officially render them less effective.

The official interaction profile is defined by two pharmacokinetic risk areas: the chelation-mediated impaired absorption of Doxycycline by metallic salts and its accelerated clearance caused by certain enzyme-inducing anti-epileptics. Furthermore, the profile includes pharmacodynamic interactions that officially warn of reduced effectiveness for Oral Contraceptives and require dosage adjustment for Anticoagulant Drugs. Formal prohibitions are in place for co-administration with Isotretinoin or Methoxyflurane due to officially documented risks of severe adverse outcomes.

Mechanism of Action

The action of Vetofol (Doxycycline Hyclate) involves two fundamentally distinct and independent pharmacodynamic mechanisms: one focused on prokaryotic protein synthesis, and the other on host enzyme and cellular modulation.


Targeting Bacterial Growth by Inhibiting Protein Synthesis

This mechanism operates by acting as a bacteriostatic agent. The molecule specifically targets the bacterial 30S ribosomal subunit , reversibly binding to it to block the attachment of charged aminoacyl-tRNA. This molecular interference halts the synthesis of proteins required for growth and division, leading to the physiological effect of bacteriostasis (cessation of bacterial proliferation).


Non-Antimicrobial Modulation of Tissue-Degrading Enzymes

Separately, the drug acts as an immunomodulator by inhibiting a family of enzymes involved in extracellular matrix degradation, known as Matrix Metalloproteinases (MMPs), particularly MMP-8. By chelating the zinc cofactor required for MMP activity, the drug modulates the enzymatic breakdown of connective tissue components, such as collagen, resulting in the maintenance of extracellular matrix structure.


Suppression of Pro-Inflammatory Mediators

This aspect of the immunomodulatory action involves modulating the host's inflammatory response at the cellular level. The drug decreases the production and release of pro-inflammatory cytokines (e.g., TNF-alpha) and limits the formation of Reactive Oxygen Species (ROS) by immune cells. This reduces excessive inflammatory signaling and results in the modulation of the systemic inflammatory profile.

Dosage and Administration Information

Vetofol (Doxycycline Hyclate) is administered via several officially recognized methods, primarily the Oral route (capsule, tablet, or suspension) and Intravenous (IV), with a localized Subgingival option available for certain long-term supportive uses. The official dosage is strictly defined by the intended clinical application, establishing two distinct usage regimens.

For systemic antimicrobial use, the prescribed protocol typically involves an initial loading dose of 200 mg on the first day, often divided into 100 mg doses administered every 12 hours. This is followed by a maintenance dose of 100 mg once daily. Conversely, for chronic supportive use, a low-dose regimen of 20 mg is administered twice daily (every 12 hours).

Administration Requirements

The duration of use varies based on the purpose, ranging from short courses of 7 to 14 days for acute issues to long-term plans extending up to nine months for chronic care. Specific administration conditions must be observed: oral doses must be taken with adequate fluid intake (e.g., at least 100 mL of water) and the patient must be in an upright position (sitting or standing) and remain upright for at least 30 minutes after intake. This procedural constraint helps ensure proper transit. Standard protocols include a weight-based regimen for pediatric patients under 45 kg, while no dose adjustment is necessary for patients with impaired renal function.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials

Studies examined how the drug may affect pain signaling pathways. Studies have explored whether the drug is associated with changes in mobility and chronic back pain.

Clinical research generally centered on evaluating whether the drug was associated with short- and long-term changes in pain severity over time in patients with chronic musculoskeletal conditions.


Key Efficacy Findings

Trial Objective Evaluated
Trial 1: Acute Pain Management Studies investigated whether taking the drug was associated with a change in inflammation markers and the time to reported improvement in pain.
Trial 2: Long-term Use Research explored the drug’s association with changes in patient-reported pain levels after 12 weeks of administration.
Trial 3: Combination Therapy Clinical studies evaluated whether the drug combination was associated with changes in patient-reported quality of life.
  • Results from Trial 1: The findings of this trial examined the average change in pain scores over a 24-hour period.
  • Results from Trial 2: The study assessed patient-reported daily function and overall pain perception. Research compared the current drug formulation to another specific treatment.
  • Results from Trial 3: The findings were used to assess the change in health status based on specific patient questionnaires.

Safety and Administration Research

Research has examined the drug's safety profile across various patient groups. Research has been conducted to understand the drug’s potential side effects and the pharmacokinetics of various administration methods.

  • Safety Profile: Studies included or excluded people with condition X in their design. The potential adverse events most frequently reported during the examination of the study group involved gastrointestinal issues.
  • Administration: Research examined the pharmacokinetics of the drug when taken with food. Another trial examined pharmacokinetics associated with various dose strengths.

Key Studies & References Relieving Acute Pain (RAP) Study: A Pilot Study (Trial comparing pain management strategies including NSAIDs, focusing on acute trauma pain and dosing)

Frequently Asked Questions (FAQ)

Common questions about Vetofol (FAQ)


Q: Can older adults safely use Vetofol?

According to official product information, older adults generally follow the standard dosing guidelines for Vetofol. Regulatory documents do not specify a need for a dedicated dose adjustment solely based on advanced age. Regulatory documents indicate that for patients with impaired kidney function, a specific dose adjustment is generally not necessary for this medication.


Q: Is there a generic version of Vetofol available?

Yes, the active ingredient in Vetofol is Doxycycline Hyclate, a semi-synthetic compound. Doxycycline is a commonly used and well-established medication that is widely available in generic forms.


Q: Can Vetofol be safely stopped suddenly, or does it need to be tapered?

For antimicrobial use (treating an infection), official guidance advises that the full course of Vetofol should be completed. This approach is intended to reduce the potential for infection relapse or the development of bacterial resistance. The decision on whether to gradually reduce or taper the medication, particularly for long-term treatments like inflammatory support, is based on the specific condition and the assessment of a health professional.


Q: Are there any specific lifestyle changes recommended while taking Vetofol?

Regulatory documents state that caution is needed regarding sun exposure. Due to the risk of photosensitivity (an exaggerated sunburn reaction), protective measures such as wearing appropriate clothing and using sunscreen are stated as necessary precautions when exposed to sunlight. For oral administration, official guidance outlines specific administration conditions, including remaining in an upright position for at least 30 minutes after taking the dose.


Q: Are there any restrictions on driving or operating machinery while on Vetofol?

Official labeling notes that side effects affecting the nervous system, such as dizziness or headache, are possible. Official labeling advises that individuals should be aware of their response to the medication before performing tasks that require full mental alertness, such as driving or operating machinery.


Q: Is Vetofol approved for use in all countries?

The core active ingredient, Doxycycline, is recognized globally and is listed on the World Health Organization's List of Essential Medicines. It is approved by major regulatory agencies worldwide, including the US FDA and the European EMA. However, the specific brand name Vetofol and its precise indications may vary by country.


Q: Can environmental factors affect how well Vetofol works?

Yes, environmental factors related to storage can affect the quality of the medication. Official requirements state that Vetofol must be stored at a controlled room temperature and protected from both light and excessive moisture. Storage outside of these recommended conditions may affect the product's stability and intended effectiveness.


Q: Is Vetofol linked to weight gain or loss?

Weight changes are not consistently listed as a common or frequent adverse reaction in the core regulatory documents that cover the most common side effects. Concerns regarding changes in weight during treatment should be discussed with a health professional.


Q: Does Vetofol affect hormone levels?

Official product information notes a specific drug interaction with oral contraceptives. Concurrent use of Vetofol may make combined hormonal birth control pills less effective, potentially requiring the use of alternative or barrier methods of contraception.


Q: Is there an antidote for Vetofol overdose?

There is no specific antidote available for an overdose of the active ingredient in Vetofol. If an overdose occurs, clinical management is supportive, focusing on monitoring and managing symptoms as no specific antidote is available.


Q: What are the signs of a serious allergic reaction to Vetofol?

Serious allergic reactions are rare, but symptoms may indicate a need for prompt medical evaluation. Signs of a severe hypersensitivity reaction may include swelling of the face, tongue, or throat; difficulty breathing; or a severe, widespread skin rash often with blistering.


Q: Is Vetofol often used in combination with other therapies?

Yes, Vetofol is frequently used as an adjunctive treatment (a treatment used in addition to the primary therapy) for certain chronic conditions, such as supportive care for gum disease. It is also often part of a combination regimen for treating complex bacterial infections.

How should Vetofol be stored and disposed of?

The storage and disposal of Vetofol (Doxycycline Hyclate) must follow strict regulatory guidelines to ensure stability and environmental protection.

Official Storage Requirements

Requirement Specific Condition
Temperature Store at controlled room temperature (e.g., below 25 C (77 F)).
Environmental Protect from light and moisture; keep container tightly closed and out of direct sunlight.
Packaging Must be dispensed in a tight, light-resistant container.
Child Safety Store out of the sight and reach of children.

Stability and Disposal Rules

Any portion of the medicine mixed with food or liquid for immediate administration must not be stored for later use. All unused or expired Vetofol must be disposed of in accordance with all applicable laws and regulations. The preferred method is a drug take-back program. Otherwise, follow the standard non-flush guideline: mix the product with an unappealing substance, place it in a sealed container, and discard it in household trash to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vetofol found in:

A-Z Index: